Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2013 May 27;169(4):922–932. doi: 10.1111/bph.12171

Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE)

Antonia Asimakopoulou 1,*, Panagiotis Panopoulos 1,*, Christos T Chasapis 1, Ciro Coletta 2, Zongmin Zhou 3, Giuseppe Cirino 4, Athanassios Giannis 5, Csaba Szabo 2, Georgios A Spyroulias 1, Andreas Papapetropoulos 1
PMCID: PMC3687671  PMID: 23488457

Abstract

Background and Purpose

Hydrogen sulfide (H2S) is a signalling molecule that belongs to the gasotransmitter family. Two major sources for endogenous enzymatic production of H2S are cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). In the present study, we examined the selectivity of commonly used pharmacological inhibitors of H2S biosynthesis towards CSE and CBS.

Experimental Approach

To address this question, human CSE or CBS enzymes were expressed and purified from Escherichia coli as fusion proteins with GSH-S-transferase. After purification, the activity of the recombinant enzymes was tested using the methylene blue method.

Key Results

β-cyanoalanine (BCA) was more potent in inhibiting CSE than propargylglycine (PAG) (IC50 14 ± 0.2 μM vs. 40 ± 8 μM respectively). Similar to PAG, L-aminoethoxyvinylglycine (AVG) only inhibited CSE, but did so at much lower concentrations. On the other hand, aminooxyacetic acid (AOAA), a frequently used CBS inhibitor, was more potent in inhibiting CSE compared with BCA and PAG (IC50 1.1 ± 0.1 μM); the IC50 for AOAA for inhibiting CBS was 8.5 ± 0.7 μM. In line with our biochemical observations, relaxation to L-cysteine was blocked by AOAA in aortic rings that lacked CBS expression. Trifluoroalanine and hydroxylamine, two compounds that have also been used to block H2S biosynthesis, blocked the activity of CBS and CSE. Trifluoroalanine had a fourfold lower IC50 for CBS versus CSE, while hydroxylamine was 60-fold more selective against CSE.

Conclusions and Implications

In conclusion, although PAG, AVG and BCA exhibit selectivity in inhibiting CSE versus CBS, no selective pharmacological CBS inhibitor is currently available.

Keywords: aminooxyacetic acid, cystathionine β-synthase, cystathionine γ-lyase, DL-propargylglycine, hydrogen sulfide, nitric oxide, pyridoxal-5′-phosphate, β-cyano-L-alanine

Introduction

Hydrogen sulfide was first noticed in the biomedical literature as a poisonous, colourless, flammable gas with the characteristic foul odour of rotten eggs (Kimura, 2010; Wang, 2012). It can be derived from the bacterial breakdown of organic matter that occurs in swamps and sewers under anoxic conditions. It is also detected in volcanic gases, natural gas, and well waters, and is also produced by manmade activities (Szabo, 2007). More recently, it was discovered that H2S production is not restricted to bacteria, but higher eukaryotes, including humans, produce small amounts of H2S and use it as a signalling molecule (Li et al., 2011; Paul and Snyder, 2012; Wang, 2012). The biological roles of endogenous H2S are multiple and rapidly expanding. Hydrogen sulfide exerts multiple effects in most organ systems including the central and peripheral nervous systems, the cardiovascular, gastrointestinal and respiratory systems; H2S also participates in the regulation of cellular metabolism and immunological/inflammatory responses (Szabo, 2007; Lavu et al., 2010; Whiteman et al., 2010; Whiteman and Winyard, 2011; Wang, 2012).

Much of the enzymatically generated H2S is derived from two pyridoxal-5′-phosphate (PLP)-dependent enzymes responsible for the metabolism of L-cysteine (L-cys): cystathionine β synthase (CBS) and cystathionine γ lyase (CSE) (Szabo, 2007; Wang, 2012); a third pathway that catalyses the production of H2S from L-cys via the combined action of 3-mercaptopyruvate sulfurtransferase and cysteine aminotransferase has also been described (Kimura, 2010). CSE and CBS catalyse several H2S-generating reactions using cysteine and/or homocysteine as substrates (Chiku et al., 2009; Singh et al., 2009; Kabil and Banerjee, 2010; Wang, 2012). CBS is the predominant H2S-generating enzyme in the brain and nervous system and is highly expressed in liver and kidney, while CSE is mainly expressed in the liver and in vascular and non-vascular smooth muscle (Szabo, 2007; Whiteman and Winyard, 2011; Wang, 2012).

To study the role of this novel gasotransmitter, investigators have relied on genetic models, knock-down of H2S-producing enzymes by siRNA and on pharmacological inhibitors. As genetic and siRNA approaches require additional expertise and access to specialized facilities, most researchers rely on pharmacological inhibitors. The most commonly used agents to inhibit H2S biosynthesis include propargylglycine (PAG), β-cyanoalanine (BCA), aminooxyacetic acid (AOAA), trifluoroalanine and hydroxylamine (HA) (Szabo, 2007; Whiteman et al., 2011; Wang, 2012). PAG and BCA are claimed to be specific inhibitors of CSE, while AOAA is often used as a selective CBS inhibitor; however, their selectivity towards these two H2S-producing enzymes has not been rigorously tested. In the present study, we set out to determine whether selective inhibitors for CBS and CSE truly exist and to evaluate if studies employing the currently available pharmacological tools can reach reliable conclusions regarding the origin of H2S in biological responses.

Methods

Materials

L-cys, D-cysteine, homocysteine, PLP, δ-aminolevulinic acid (δ-ALA), GSH, protease inhibitor cocktail, Coomassie blue R-250, zinc acetate (ZnAc), trichloroacetic acid (TCA), N,N-dimethyl-p-phenylenediamine-sulfate, iron(III) chloride (FeCl3), phenylephrine (PE), sodium hydrogen sulfide (NaSH), DL-PAG, β-cyano-L-alanine (BCA), HA, AOAA, methylselenocysteine, isoniazid, hydralazine, trifluoroalanine, aminoethoxyvinylglycine (AVG) and pargyline were obtained from Sigma-Aldrich (Taufkirchen, Germany). D-cycloserine was obtained from ABCR GmbH & Co KG (Karlsruhe, Germany). Escherichia coli BL21 (DE3) Codon Plus cells were obtained from Stratagene. Luria–Bertani (LB) broth medium and agar were purchased from Fischer Scientific (Loughborough, UK). GSTrap FF columns were obtained from GE Healthcare (Uppsala, Sweden). Isopropyl-b-D-thiogalactopyranoside (IPTG), TritonX-100, DTT, tetramethylethylenediamine, ammonium persulfate and ampicillin were obtained from Applichem Biochemica (Darmstadt, Germany). PBS, tris/glycine/SDS buffer (TGF), Tris–HCl, PVDF membrane and DC protein assay kit were obtained from Biorad (Hercules, CA, USA). RIPA, NuPAGE LDS sample buffer and NuPAGE sample-reducing agent were purchased from Invitrogen (Carlsbad, CA, USA); Starting Block T20 blocking buffer and chemiluminescent substrate were purchased from Thermo Scientific (BioAnalytica S.A, Athens, Greece). CBS antibody was obtained from Abnova (Aachen, Germany) and CSE antibody was purchased from ProteinTech (Herford, Germany). Secondary antibodies were purchased from Cell Signaling Technologies (Beverly, MA, USA).

Plasmids, bacterial strains and media

E. coli BL21 (DE3) Codon Plus was used as the host strain to express recombinant human CSE or CBS. CSE cDNA was cloned into pGEX-4T3 and CBS into pGEX-Kg to create N-terminal GSH-S-transferase (GST) fusion proteins. The expression vectors were transformed and plated on LB-agar plates, supplemented with ampicillin (100 μg·mL−1).

Protein expression and purification

The expression and purification of CSE and CBS was performed as described previously with modifications (Frank et al., 2008; Huang et al., 2009). Briefly, BL21(DE3) Codon Plus cells containing either the expression vector pGEX-4T3/GST-CSE or pGEX-Kg/GST-CBS were grown at 37°C and 180 r.p.m. in LB broth medium containing 100 μg·mL−1 ampicillin to an absorption of 0.6–0.8 at 600 nm. In addition, 0.3 mM δ-ALA was added to the culture containing pGEX-Kg/GST-CBS. Then protein expression was induced by addition of 0.1 mM IPTG. Cells containing pGEX-4T-3/GST-CSE were incubated overnight at 18°C, whereas cells containing pGEX-Kg/GST-CBS were incubated overnight at 30°C. Culture was then centrifuged at 4°C and 5000× g for 10 min and the cell pellet was resuspended in PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.8) and stored at −20°C overnight. After thawing, the suspension was sonicated in lysis buffer containing PBS and protease inhibitor cocktail for GST-CSE and PBS, 5 mM DTT, 1% Triton X-100, 100 μM PLP and protease inhibitor cocktail for GST-CBS. After centrifugation at 4°C for 30 min, the soluble fraction containing either the GST-CSE or the GST-CBS recombinant protein was loaded onto a GSTrap FF 1 mL affinity column previously equilibrated with binding buffer PBS. The column was consecutively washed with five column volumes of binding buffer. Proteins attached to the column, including GST-CSE or GST-CBS recombinant proteins, were eluted with five column volumes of elution buffer (50 mM Tris–HCl, 10 mM reduced GSH, pH 8.0) and then dialysed and concentrated in 10 mM sodium phosphate buffer pH 8.2 and DTT 1 mM. The purity of the recombinant enzymes was checked by SDS-PAGE on 12% polyacrylamide gels after staining of protein bands with Coomassie Blue R-250. Protein concentration was determined using the DC protein assay kit.

Measurement of H2S production (methylene blue assay)

H2S determination was performed according to Stipanuk and Beck (1982) with some modifications. In the case of the CSE enzyme, each test consisted of a 100 μL reaction mixture containing 5 μg of the purified CSE enzyme, 0.01 mM PLP, 1 mM L-cys and 50 mM sodium phosphate buffer pH 8.2. For the CBS enzyme, the reaction mixture contained the same as for the CSE plus 1 mM homocysteine. The inhibitors were added to the reaction 15 min before L-cys was added to the solution. Reaction was initiated by transferring the Eppendorf tubes from ice to a 37°C shaking water bath. After 60 min of incubation at 37°C, unless otherwise indicated, the reaction was terminated by adding 1% ZnAc to trap H2S followed by 10% TCA to precipitate proteins. Subsequently, N,N-dimethyl-p-phenylenediamine-sulfate in 7.2 M HCl was immediately followed by addition of FeCl3 in 1.2 M HCl. The absorbance of the resulting solution was measured at 655 nm. H2S content was calculated against a calibration curve of standard H2S solutions. GST was not removed from the fusion proteins as it has been previously reported that the presence of GST does not affect activity. Furthermore, GST did not interfere with the assay, since no H2S-synthesizing activity was observed in a control activity experiment with GST alone (Huang et al., 2010).

Isolated rat aortic ring assay

All procedures were approved by the Institutional Animal Care and Use Committee of the University of Texas Medical Branch in accordance with the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals. Sprague–Dawley rats (∼300 g) were housed in an air-conditioned environment (22 ± 1°C, 50 ± 5% relative humidity, 12 h light-dark cycle) with free access to food and water. The animals were allowed at least 5 days to acclimatize. Animals were killed by exsanguination under deep anaesthesia by ketamine/xylazine (the femoral vein was excised). Death was ensured by opening the chest. Thoracic aortic rings (2–3 mm in length) were cut and placed in organ baths (5 mL) filled with oxygenated (95% O2 to 5% CO2) Krebs–Henseleit solution at 37°C, mounted to isometric force transducers and connected to a PowerLab data acquisition system. Aortic rings were allowed to equilibrate under a resting tension of 1 g and subsequently contracted with PE (1 μM). Once a plateau was reached, cumulative concentration–response curves to D-cysteine or L-cys were performed. In some experiments, aortic rings were incubated with AOAA (1 mM) or PAG (3 mM) 20 min before PE challenge. The experiments were repeated on at least four aortic rings, each from different rats. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al., 2010; McGrath et al., 2010).

Western blotting

Tissues were homogenized in RIPA in the presence of proteases inhibitors. Protein extracts were then diluted in NuPAGE LDS Sample Buffer (Invitrogen), reduced by NuPAGE sample-reducing agent and denatured at 70°C for 10 min. Samples were subjected to SDS-PAGE and transferred to PVDF membranes. Membranes were incubated with Starting Block T20 blocking buffer and then probed overnight with the indicated primary antibodies. Following incubation with an appropriate secondary antibody, immunoreactive proteins were detected using a chemiluminescent substrate.

Statistical analysis

All data are presented as means ± SEM. Statistical analysis was performed by one-way anova followed by Newman–Keuls multiple comparison test. Differences were considered statistically significant when P-value was less than 0.05. GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was used for all the statistical analysis.

Results

Purification of CSE and CBS and activity optimization for H2S measurement

Human CSE and CBS proteins were expressed in a heterologous system using E. coli. Recombinant proteins were then purified from bacterial lysates by affinity chromatography on GSH columns; SDS-PAGE revealed that both proteins were recovered in a highly purified form (Figure 1A,B). Moreover, the absorption spectrum of human CBS exhibited a peak at 430 nm suggesting the presence of haem in the recombinant protein (Figure 1C).

Figure 1.

Figure 1

Open in a new tab

Purification of recombinant CSE and CBS. Representative SDS-PAGE of fractions after different purification steps of recombinant GST-CSE (A) and GST-CBS (B) from bacterial cell lysates. Lanes: M, protein marker. 1(A) cell lysate before purification; 1(B) PBS after GSTrap column calibration; 2(A) PBS after GSTrap column calibration; 2(B) cell lysate before purification; (3) cell lysate after purification; (4,5) first and second wash with binding buffer respectively; (6) eluted GST-CSE or GST-CBS; (7) elution buffer. (C) UV absorption spectra of CBS in 10 mM phosphate buffer pH = 8.2. The peak at 430 nm indicates the presence of haem in CBS.

We next tested the catalytic activity of purified CSE and CBS by measuring their ability to produce H2S. Production of H2S was proportional to the amount of enzyme used (Figure 2A). As 5 μg of enzyme was the smallest amount that led to H2S synthesis that was well above the detection limit, all subsequent experiments were performed using this amount of protein. Also, all reactions were allowed to proceed for 60 min, as during the first 60 min H2S levels generated were maximal giving us optimal signal to noise readings, while reactions were still in the linear phase (Figure 2B). We then determined the amount of PLP, a cofactor for both CBS and CSE that is needed for H2S generation. Results in Figure 2C showed that 0.01 mM PLP is sufficient to produce maximal amounts of H2S from CSE; CBS isolated probably had enough PLP bound as the bacterial lysis buffer contained PLP. Both CSE and CBS generated H2S in the presence of L-cys (Figure 2D,E). However, in the presence of homocysteine, CBS produced fourfold greater amounts of H2S. In agreement to our finding, Singh et al. observed that human CBS can generate H2S from cysteine, albeit with lower kcat values than from cysteine and homocysteine (Singh et al., 2009). Therefore, as CBS preferentially catalyses the reaction with both homocysteine and cysteine as substrates, this reaction was used to evaluate the inhibitor compounds. Human CSE did not generate detectable H2S levels under the conditions employed when homocysteine was used as a substrate (data not shown).

Figure 2.

Figure 2

Open in a new tab

H2S production from purified CSE (grey bars) and CBS (black bars). H2S generated: (A) by different amounts of CSE and CBS with 1 mM L-cys as substrate; (B) at different time intervals using 5 μg of either CSE or CBS; and (C) at different concentrations of PLP; (D) by purified (5 μg) CSE at the indicated concentrations of L-cys; and (E) by purified CBS (5 μg) in the absence or presence of the indicated concentrations of L-cys and homocysteine (Hcy). Data are presented as mean ± SEM; n = 6; *P < 0.05 versus control CSE, #P < 0.05 versus control CBS (for A and B); *P < 0.05 versus –PLP (C); *P < 0.05 versus (–) L-cys or –L-cys/Hcy (for D and E).

Effect of inhibitors on CSE and CBS activity

Initially, we tested the effect of several commercially available inhibitors of H2S synthesis on CSE. Our results show that BCA is a more potent CSE inhibitor than PAG with IC50 of 14 and 40 μM respectively (Table 1 and Figure 3A,B). Surprisingly, AOAA, a frequently used ‘selective’ CBS inhibitor, also inhibited CSE with an IC50 of 1.1 μM (Figure 3D). In addition, trifluoroalanine and HA also blocked CSE, with the former being less potent than the latter (Figure 3C and E; Table 1). The most potent inhibitor of all, among the ones tested, was L-AVG (Figure 3F).

Table 1.

IC50 values of commonly used H2S inhibitors for CSE and CBS

Compounds CSE, IC50 (μM) CBS, IC50 (μM)
PAG 40.0 ± 8.0 –
BCA 14.0 ± 0.16 –
HA 4.83 ± 0.31 278.0 ± 22.0
AOAA 1.09 ± 0.12 8.52 ± 0.71
Trifluoroalanine 289.0 ± 7.0 66.0 ± 9.0
AVG 1.0 ± 0.1 –
Open in a new tab

Figure 3.

Figure 3

Open in a new tab

Inhibition of H2S production from purified CSE by different inhibitors. Each reaction was performed in the presence of 100 μL sodium phosphate buffer containing 5 μg of CSE, 10 μM PLP and 1 mM of L-cys as substrates. Inhibitors were added 15 min before the L-cys at the indicated concentration and reactions allowed to proceed for 60 min (A–F). Data are presented as mean ± SEM; n = 9; *P < 0.05 versus control.

Subsequently, the ability of the above-mentioned inhibitors on CBS was tested ( Figure 4). Neither PAG nor AVG had any effect on CBS activity up to the concentration used (10 and 1 mM respectively; Figure 4A,F). However, BCA reduced CBS activity when added in excess of 1 mM (Figure 4B). AOAA did inhibit CBS, but the IC50 for this enzyme was higher than the IC50 for CSE (Figure 4D). Trifluoroalanine and HA also reduced CBS activity, with trifluoroalanine being fourfold more potent than HA (Figure 4C,E).

Figure 4.

Figure 4

Open in a new tab

Inhibition of H2S production from purified CBS by different inhibitors. Each reaction was performed in the presence of 100 μL sodium phosphate buffer containing 5 μg of CBS, 10 μM PLP, 1 mM of L-cys and 1 mM homocysteine as substrates. Inhibitors (A–F) were added 15 min before the substrates at the indicated concentration and reactions allowed to proceed for 60 min. Data are presented as mean ± SEM; n = 9; *P < 0.05 versus control.

Effect of NO on CSE and CBS activity

HA is known to release NO (Gross, 1985). Thus, we tested whether the inhibitory activity of this molecule on CBS and CSE might be indirect, resulting from NO release. Initially, we tested the ability of HA to alter the colour development and absorbance of NaSH; these experiments showed that HA does not interfere with colour development in the methylene blue assay (data not shown). Similarly, diethylamine NONOate (DEA/NO), a NO donor, had no effect on the NaSH standard curve when used up to 100 μM. DEA/NO concentration dependently attenuated CSE activity but did not affect CBS activity (Figure 5).

Figure 5.

Figure 5

Open in a new tab

Effect of DEA/NO on CSE and CBS activity. Reactions were performed as detailed in Figures 3 and 4 in the presence of the NO donor DEA/NO. Data are presented as mean ± SEM; n = 9; *P < 0.05 versus control.

Effect of PLP-based inhibitors on CSE and CBS activity

We next tested the ability of several compounds that are clinically used and have some resemblance to the commonly used CSE/CBS inhibitors to reduce H2S production by the two enzymes studied. D-cycloserine and isoniazid, two antibiotics used against Mycobacterium tuberculosis infections, are known to inhibit multiple PLP-dependent enzymes (Riccardi et al., 2009). Both compounds showed a tendency to reduce CSE activity at 1 mM (Table 2) that for isoniazid in the case of CSE reached statistical significance. Parsalmide, an agent with anti-inflammatory, analgesic, muscle-relaxing and anxiolytic activity (Bianchetti et al., 1982), and pargyline, an antidepressant (Goldberg, 1964), which both carry C ≡ C bonds like PAG, failed to significantly reduce CSE or CBS activity (Table 2). Similarly, methylselenocysteine did not inhibit the activity of neither CBS nor CSE, suggesting that it cannot be used to replace the substrate L-cys from the catalytic centre of CSE and CBS.

Table 2.

Compounds tested as possible inhibitors of H2S production

CSE CBS
H2S production (% of control) H2S production (% of control) H2S production (% of control) H2S production (% of control)
Compounds 0.1 mM 1 mM 0.1 mM 1 mM
D-Cycloserine 83.3 ± 19.2 73.3 ± 18.6 94.2 ± 20.5 80.6 ± 21.0
Isoniazid 93.3 ± 23.0 63.3* ± 16.6 86.4 ± 9.4 88.4 ± 2.1
Parsalmide 86.7 ± 17.8 76.7 ± 11.3 88.4 ± 7.4 93.8 ± 9.9
Pargyline 96.7 ± 7.1 81.7 ± 12.5 74.0 ± 12.8 90.1 ± 14.3
Methylseleno-cysteine 85.5 ± 4.4 79.7 ± 4.3 95.5 ± 2.1 79.2 ± 5.1
Open in a new tab

Reactions were performed as detailed in the legends of Figures 3 and 4. Data are presented as mean ± SEM; n = 4–6; *P < 0.05 versus control CSE.

Effect of AOAA on H2S vasorelaxation in isolated rat aorta

We sought to determine whether AOAA, which we found to inhibit CSE activity in vitro, would also inhibit CSE-mediated responses in tissues. To this end, we used rat aortic rings that are devoid of CBS expression (Figure 6A). Exposure of rat aorta to the CSE substrate L-cys, but not D-cysteine, led to a concentration-dependent relaxation (Figure 6B). Pretreatment with the CSE inhibitor PAG blocked the L-cys-driven vasodilation. In addition, pretreatment with AOAA (in a tissue that lacks CBS) blocked L-cys-induced relaxations to the same extent as PAG, while the combined treatment of PAG and AOAA offered no greater inhibition of relaxation (Figure 6C), suggesting that AOAA also inhibits CSE in a cellular milieu.

Figure 6.

Figure 6

Open in a new tab

AOAA inhibits CSE biological activity in aortic tissue. (A) Representative Western blots depicting expression of CSE and CBS in rat tissues. (B,C) Phenylephrine contracted aortic rings were exposed to D- or L-cys in the absence (B) or presence (C) of inhibitors H2S synthesis, inhibitors AOAA and PAG (5 mM each). Data are presented as mean ± SEM; n = 5; *P < 0.05 versus control.

Discussion

The best studied inhibitor of CSE is PAG (also known as PGG), which has been co-crystallized (Sun et al., 2009) with CSE in the presence of the cofactor PLP. PAG is an antibiotic produced by Streptomyces sp. that irreversibly inhibits CSE through a ‘suicidal’ inactivation (Wang, 2012). Co-crystallization of CSE with PAG unveiled that PAG once bound obstructs, via steric hindrance, the accessibility of the substrate to the active site of the enzyme by occupying the space of the side chain of the substrate. Furthermore, PAG covalently binds and traps residue Tyr114, which is believed to facilitate the release of substrate (Clausen et al., 1998; Sun et al., 2009). To inhibit CSE, PAG is typically used at concentrations in the 1–10 mM range (Whiteman et al., 2011). In our studies, we observed that the IC50 of PAG for CSE was 40 μM. It should be noted that while DL-PAG was used in our experiments, only the L-isoform inhibits CSE; the D-isoform is metabolized and contributes to the toxicity of the compound in vivo (Konno et al., 2000). In a frequently cited manuscript by Mok et al. (2004), an IC50 of 55 μM for PAG was reported in rat liver preparations; however, the racemic form of PAG (DL- or L-) used was not disclosed in this study. In contrast to the μM IC50 values reported with purified enzyme or cell lysates, PAG, when used in functional assays such as inhibition of L-cys-induced dilation, requires mM concentrations to inhibit 50% of the response observed (Bucci et al., 2009; 2010). Similar to what has been reported in the literature, we found that 5 mM of PAG was needed to inhibit L-cys-induced relaxation; this could perhaps be attributed to limited cell membrane permeability of PAG (Szabo, 2007). In additional experiments, we observed that PAG did not inhibit the activity of recombinant human CBS, suggesting that it can indeed be used as a selective inhibitor for CSE versus CBS. However, although selective towards CSE, PAG is not devoid of drawbacks. When used at millimolar concentrations, which are needed to fully block CSE, it also inhibits other enzymes such as aspartate aminotransferase (Tanase and Morino, 1976) and alanine aminotransferase (Burnett et al., 1992).

β-cyano-L-alanine is a neurotoxic agent found in poisonous legumes responsible for outbreaks of human neurolathyrism (Ressler, 1962; Ressler et al., 1964). BCA, unlike PAG, is a reversible inhibitor of CSE; and acts by modifying the apoenzyme transiently (Whiteman et al., 2011). We found that the IC50 for BCA is lower than PAG. In line with our observations, BCA in most cases has been shown to have lower IC50 when compared with PAG in the same preparation side by side, suggesting that BCA is a more potent inhibitor than PAG (Mok et al., 2004; Tang et al., 2005; Papapetropoulos et al., 2009). However, BCA also inhibited CBS when used above 1 mM. As this concentration is frequently used by investigators in in vitro experiments, when high BCA concentrations are used results should be interpreted with caution and not taken to automatically prove CSE involvement. In addition, much like PAG, BCA has been shown to inhibit additional enzymes such as aspartate β-decarboxylase and alanine aminotransferase (Alston et al., 1980; Cornell et al., 1984).

AOAA is a general inhibitor for aminotransferases and was proposed to also inhibit CBS (Rej, 1977). However, many studies have used it claiming it to be a CBS selective inhibitor (d'Emmanuele di Villa Bianca et al., 2009; Roy et al., 2011). To test whether AOAA is truly selective towards CBS, we tested this compound using recombinant CBS and CSE. We observed that AOAA inhibited both enzymes, with the latter being inhibited at lower AOAA concentrations. Moreover, to determine whether inhibition of CSE by AOAA also occurs at the tissue level, we used rat aortic rings. In spite of the absence of detectable CBS, AOAA inhibited the vasodilatory responses triggered by L-cys, suggesting that like in biochemical assays, AOAA is an effective CSE inhibitor and should no longer be used to selectively inhibit CBS in vitro and in vivo.

Trifluoroalanine has been shown to irreversibly inhibit a number of PLP-dependent enzymes that catalyse β- or γ-elimination reactions (Silverman and Abeles, 1976; Singh et al., 2009). Among the enzymes known to be inhibited are CSE, CBS and cystathionine γ synthase, the latter two are members of the transsulfuration pathway that exists in plants and bacteria (Steegborn et al., 1999). It has been proposed that the inactivation is due to covalent modification of the enzyme (Silverman and Abeles, 1977; Steegborn et al., 1999). Herein we observed that trifluoroalanine inhibited both CBS and CSE, and exhibited a fourfold selectivity for CBS. Another inhibitor that has been less frequently used to block H2S generation is AVG. AVG was discovered in a fermentation broth of an unidentified Streptomyces sp. as an amino acid antimetabolite that inhibited the growth of Streptomyces cellulosae (Pruess et al., 1974). AVG was previously reported to inhibit some of the enzymes of the transsulfuration pathway (Clausen et al., 1997). We observed that the IC50 of AVG for CSE is 1 μM, making AVG the most potent available inhibitor for this enzyme. Interestingly, AVG also failed to reduce CBS activity when used up to 1 mM, suggesting that in addition to being a potent CSE inhibitor, it is also the most selective for CSE. It should however be emphasized that in spite of its great selectivity for CSE over CBS, AVG has well-documented effects on other PLP-dependent enzymes. These effects should therefore be thoroughly considered when assessing the role of this compound in cell culture, tissue baths and in vivo.

HA is a product of cellular metabolism and a putative intermediate in the conversion of L-arginine to NOHA (DeMaster et al., 1989). HA has reducing and antioxidant properties and has the ability to release the gaseous mediator NO and form NO− (nitroxyl ions) (Gross, 1985). HA is used as a general inhibitor of many haem-containing enzymes, including CBS, although some non-haem molecular targets of HA have also been observed (Spooren and Evelo, 1997). In our study, we observed that it exhibits a 60-fold selectivity towards CSE, but it also inhibits CBS at higher concentrations.

In higher, but not lower, eukaryotes CBS carries a haem group that is bound to its N-terminus making CBS the only known PLP-containing haemprotein (Wang, 2012). The function of the haem on CBS is not entirely clear. This prosthetic group is not necessary for the catalytic action of CBS, as removal of haem lowers but does not abolish the activity of human CBS (Evande et al., 2004). It was recently proposed that haem might have a structural role, facilitating folding and promoting protein stability (Majtan et al., 2008). Binding of NO or CO to the haem moiety has been proposed to regulate enzymatic activity (Taoka and Banerjee, 2001). Although both CO and NO can inhibit CBS activity, NO binds 200-fold less tightly than CO. As HA liberates NO, we sought to determine whether the inhibition of CBS by HA was a direct one or was due to the NO produced. To this end, we used the NO donor DEA/NO. We observed that CBS was resistant at concentrations of DEA/NO up to 250 μM. In line with this finding, Eto and Kimura (2002) reported that neither 3-morpholinosydnonimine nor S-nitroso-N-acetylpenicillamine up to 300 μM affects CBS activity. Since HA already inhibits approximately 30% of CBS at 100 μM, we conclude that the inhibition of CBS by HA is direct, rather than through the release of NO. In addition, DEA/NO did not inhibit CSE activity at 5 μM and caused a maximal 75% inhibition at 250 μM, whereas addition of 5 μM HA inhibited approximately 60% of CSE activity and 50 μM abolished CSE activity, suggesting that the action of HA is direct and NO independent. Although the mechanism through which NO inhibits CSE is unknown, it might involve nitrosylation of critical cysteine residues in CSE; however, the NO-induced inhibition of CSE is of pharmacological and not physiological importance, as μM concentrations are needed to observe this effect.

In summary, after testing a variety of frequently used inhibitors for CSE and CBS, we have found that AVG is the most potent and selective of all for CSE. PAG also exhibits selectivity towards CSE, but its potency is lower than that of AVG. BCA, although selective for CSE, also inhibits CBS when used at high concentrations (Figure 7). In contrast, none of the compounds tested exhibited significant selectivity towards CBS. We conclude that design and development of new inhibitors for each of the H2S-synthesizing enzymes is an unmet need for the field so that the role of H2S-regulated pathways in the development and treatment of disease can be evaluated.

Figure 7.

Figure 7

Open in a new tab

Chemical structures of compounds that block CSE selectively or preferentially.

Acknowledgments

This work has been co-financed by the European Union (European Social Fund – ESF) and Greek National Funds through the Operational Program ‘Education and Lifelong Learning’ of the National Strategic Reference Framework (NSRF) – Research Funding Program: Thalis; investing in knowledge society through the European Social Fund (MIS380259) and Aristeia 2011 (1436) to A. P., by Thorax Foundation (Athens, Greece), by EU FP7 REGPOT CT-2011-285950 – ‘SEE-DRUG and by the COST Action BM1005 (ENOG: European Network on Gasotransmitters). C. C. and C. S. were supported by a grant (7–12-BS-184) from the American Diabetes Association.

Glossary

AOAA

aminooxyacetic acid

AVG

aminoethoxyvinylglycine

BCA

β-cyano-L-alanine

CBS

cystathionine β-synthase

CSE

cystathionine γ-lyase

DEA/NO

diethylamine NONOate

GST

GSH-S-transferase

H2S

hydrogen sulfide

IPTG

isopropyl-b-D-thiogalactopyranoside

L-cys

L-cysteine

DL-PAG

propargylglycine

PLP

pyridoxal-5′-phosphate

δ-ALA

δ-aminolevulinic acid

Conflict of interest

The authors state no conflict of interest.

References

  1. Alston TA, Porter DJ, Mela L, Bright HJ. Inactivation of alanine aminotransferase by the neurotoxin beta-cyano-L-alanine. Biochem Biophys Res Commun. 1980;92:299–304. doi: 10.1016/0006-291x(80)91552-1. [DOI] [PubMed] [Google Scholar]
  2. Bianchetti A, Lavezzo A, Carminati P. The non-steroidal anti-inflammatory agent parsalmide prevents aspirin-induced H+ back diffusion from the gastric lumen of the rat. J Pharm Pharmacol. 1982;34:51–53. doi: 10.1111/j.2042-7158.1982.tb04679.x. [DOI] [PubMed] [Google Scholar]
  3. Bucci M, Mirone V, Di Lorenzo A, Vellecco V, Roviezzo F, Brancaleone V, et al. Hydrogen sulphide is involved in testosterone vascular effect. Eur Urol. 2009;56:378–383. doi: 10.1016/j.eururo.2008.05.014. [DOI] [PubMed] [Google Scholar]
  4. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol. 2010;30:1998–2004. doi: 10.1161/ATVBAHA.110.209783. [DOI] [PubMed] [Google Scholar]
  5. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science. 1992;257:401–403. doi: 10.1126/science.1378650. [DOI] [PubMed] [Google Scholar]
  6. Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V, Banerjee R. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J Biol Chem. 2009;284:11601–11612. doi: 10.1074/jbc.M808026200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clausen T, Huber R, Messerschmidt A, Pohlenz HD, Laber B. Slow-binding inhibition of Escherichia coli cystathionine beta-lyase by L-aminoethoxyvinylglycine: a kinetic and X-ray study. Biochemistry. 1997;36:12633–12643. doi: 10.1021/bi970630m. [DOI] [PubMed] [Google Scholar]
  8. Clausen T, Huber R, Prade L, Wahl MC, Messerschmidt A. Crystal structure of Escherichia coli cystathionine gamma-synthase at 1.5 A resolution. EMBO J. 1998;17:6827–6838. doi: 10.1093/emboj/17.23.6827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cornell NW, Zuurendonk PF, Kerich MJ, Straight CB. Selective inhibition of alanine aminotransferase and aspartate aminotransferase in rat hepatocytes. Biochem J. 1984;220:707–716. doi: 10.1042/bj2200707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. DeMaster EG, Raij L, Archer SL, Weir EK. Hydroxylamine is a vasorelaxant and a possible intermediate in the oxidative conversion of L-arginine to nitric oxide. Biochem Biophys Res Commun. 1989;163:527–533. doi: 10.1016/0006-291x(89)92169-4. [DOI] [PubMed] [Google Scholar]
  11. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, Mirone V, Imbimbo C, Fusco F, et al. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci U S A. 2009;106:4513–4518. doi: 10.1073/pnas.0807974105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Eto K, Kimura H. A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase. J Biol Chem. 2002;277:42680–42685. doi: 10.1074/jbc.M205835200. [DOI] [PubMed] [Google Scholar]
  13. Evande R, Ojha S, Banerjee R. Visualization of PLP-bound intermediates in hemeless variants of human cystathionine beta-synthase: evidence that lysine 119 is a general base. Arch Biochem Biophys. 2004;427:188–196. doi: 10.1016/j.abb.2004.04.027. [DOI] [PubMed] [Google Scholar]
  14. Frank N, Kent JO, Meier M, Kraus JP. Purification and characterization of the wild type and truncated human cystathionine beta-synthase enzymes expressed in E. coli. Arch Biochem Biophys. 2008;470:64–72. doi: 10.1016/j.abb.2007.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldberg LI. Monoamine oxidase inhibitors. Adverse reactions and possible mechanisms. JAMA. 1964;190:456–462. [PubMed] [Google Scholar]
  16. Gross P. Biologic activity of hydroxylamine: a review. Crit Rev Toxicol. 1985;14:87–99. doi: 10.3109/10408448509023765. [DOI] [PubMed] [Google Scholar]
  17. Huang S, Chua JH, Yew WS, Sivaraman J, Moore PK, Tan CH, et al. Site-directed mutagenesis on human cystathionine-gamma-lyase reveals insights into the modulation of H2S production. J Mol Biol. 2009;396:708–718. doi: 10.1016/j.jmb.2009.11.058. [DOI] [PubMed] [Google Scholar]
  18. Huang S, Chua JH, Yew WS, Sivaraman J, Moore PK, Tan CH, et al. Site-directed mutagenesis on human cystathionine-gamma-lyase reveals insights into the modulation of H2S production. J Mol Biol. 2010;396:708–718. doi: 10.1016/j.jmb.2009.11.058. [DOI] [PubMed] [Google Scholar]
  19. Kabil O, Banerjee R. Redox biochemistry of hydrogen sulfide. J Biol Chem. 2010;285:21903–21907. doi: 10.1074/jbc.R110.128363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. NC3Rs Reporting Guidelines Working Group. Br J Pharmacol. 2010;160:1577–1579. doi: 10.1111/j.1476-5381.2010.00872.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kimura H. Hydrogen sulfide: from brain to gut. Antioxid Redox Signal. 2010;12:1111–1123. doi: 10.1089/ars.2009.2919. [DOI] [PubMed] [Google Scholar]
  22. Konno R, Ikeda M, Yamaguchi K, Ueda Y, Niwa A. Nephrotoxicity of d-propargylglycine in mice. Arch Toxicol. 2000;74:473–479. doi: 10.1007/s002040000156. [DOI] [PubMed] [Google Scholar]
  23. Lavu M, Bhushan S, Lefer DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci (Lond) 2010;120:219–229. doi: 10.1042/CS20100462. [DOI] [PubMed] [Google Scholar]
  24. Li L, Rose P, Moore P. Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol. 2011;51:169–187. doi: 10.1146/annurev-pharmtox-010510-100505. [DOI] [PubMed] [Google Scholar]
  25. Majtan T, Singh L, Wang L, Kruger W, Kraus J. Active cystathionine beta-synthase can be expressed in haem-free systems in the presence of metal-substituted porphyrins or a chemical chaperone. J Biol Chem. 2008;283:34588–34595. doi: 10.1074/jbc.M805928200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1573–1576. doi: 10.1111/j.1476-5381.2010.00873.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mok YY, Atan MS, Yoke Ping C, Zhong Jing W, Bhatia M, Moochhala S, et al. Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. Br J Pharmacol. 2004;143:881–889. doi: 10.1038/sj.bjp.0706014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A. 2009;106:21972–21977. doi: 10.1073/pnas.0908047106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Paul B, Snyder S. H2S signalling through protein sulfhydration and beyond. Nat Rev Mol Cell Biol. 2012;13:499–507. doi: 10.1038/nrm3391. [DOI] [PubMed] [Google Scholar]
  30. Pruess DL, Scannell JP, Kellett M, Ax HA, Janecek J, Williams TH, et al. Antimetabolites produced by microorganisms. X. L-2-amino-4-(2-aminoethoxy)-trans-3-butenoic acid. J Antibiot (Tokyo) 1974;27:229–233. doi: 10.7164/antibiotics.27.229. [DOI] [PubMed] [Google Scholar]
  31. Rej R. Aminooxyacetate is not an adequate differential inhibitor of aspartate aminotransferase isoenzymes. Clin Chem. 1977;23:1508–1509. [PubMed] [Google Scholar]
  32. Ressler C. Isolation and identification from common vetch of the neurotoxin beta-cyano-L-alanine, a possible factor in neurolathyrism. J Biol Chem. 1962;237:733–735. [PubMed] [Google Scholar]
  33. Ressler C, Nelson J, Pfeffer M. A pyridoxal-beta-cyanoalanine relation in the rat. Nature. 1964;203:1286–1287. doi: 10.1038/2031286a0. [DOI] [PubMed] [Google Scholar]
  34. Riccardi G, Pasca MR, Buroni S. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol. 2009;4:597–614. doi: 10.2217/fmb.09.20. [DOI] [PubMed] [Google Scholar]
  35. Roy A, Khan AH, Islam MT, Prieto MC, Majid DS. Interdependency of cystathione gamma-lyase and cystathione beta-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am J Hypertens. 2011;25:74–81. doi: 10.1038/ajh.2011.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Silverman RB, Abeles RH. Inactivation of pyridoxal phosphate dependent enzymes by mono- and polyhaloalanines. Biochemistry. 1976;15:4718–4723. doi: 10.1021/bi00666a028. [DOI] [PubMed] [Google Scholar]
  37. Silverman RB, Abeles RH. Mechanism of inactivation of gamma cystathionate by beta, beta, beta trifluoroalanine. Biochemistry. 1977;16:5515–5520. doi: 10.1021/bi00644a019. [DOI] [PubMed] [Google Scholar]
  38. Singh S, Padovani D, Leslie RA, Chiku T, Banerjee R. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions. J Biol Chem. 2009;284:22457–22466. doi: 10.1074/jbc.M109.010868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Spooren AA, Evelo CT. Hydroxylamine treatment increases glutathione-protein and protein-protein binding in human erythrocytes. Blood Cells Mol Dis. 1997;23:323–336. doi: 10.1006/bcmd.1997.0150. [DOI] [PubMed] [Google Scholar]
  40. Steegborn C, Clausen T, Sondermann P, Jacob U, Worbs M, Marinkovic S, et al. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration. J Biol Chem. 1999;274:12675–12684. doi: 10.1074/jbc.274.18.12675. [DOI] [PubMed] [Google Scholar]
  41. Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J. 1982;206:267–277. doi: 10.1042/bj2060267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sun Q, Collins R, Huang S, Holmberg-Schiavone L, Anand GS, Tan CH, et al. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S. J Biol Chem. 2009;284:3076–3085. doi: 10.1074/jbc.M805459200. [DOI] [PubMed] [Google Scholar]
  43. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917–935. doi: 10.1038/nrd2425. [DOI] [PubMed] [Google Scholar]
  44. Tanase S, Morino Y. Irreversible inactivation of aspartate aminotransferases during transamination with L-propargylglycine. Biochem Biophys Res Commun. 1976;68:1301–1308. doi: 10.1016/0006-291x(76)90338-7. [DOI] [PubMed] [Google Scholar]
  45. Tang G, Adu-Sarkodie K, Kim D, Kim JH, Teefy S, Shukairy HM, et al. Modeling Cryptosporidium parvum oocyst inactivation and bromate formation in a full-scale ozone contactor. Environ Sci Technol. 2005;39:9343–9350. doi: 10.1021/es050345n. [DOI] [PubMed] [Google Scholar]
  46. Taoka S, Banerjee R. Characterization of NO binding to human cystathionine beta-synthase: possible implications of the effects of CO and NO binding to the human enzyme. J Inorg Biochem. 2001;87:245–251. doi: 10.1016/s0162-0134(01)00335-x. [DOI] [PubMed] [Google Scholar]
  47. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92:791–896. doi: 10.1152/physrev.00017.2011. [DOI] [PubMed] [Google Scholar]
  48. Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. Expert Rev Clin Pharmacol. 2011;4:13–32. doi: 10.1586/ecp.10.134. [DOI] [PubMed] [Google Scholar]
  49. Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia. 2010;53:1722–1726. doi: 10.1007/s00125-010-1761-5. [DOI] [PubMed] [Google Scholar]
  50. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond) 2011;121:459–488. doi: 10.1042/CS20110267. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES